Circular RNA Circ_0081001 Knockdown Enhances Methotrexate Sensitivity in Osteosarcoma Cells by Regulating MiR-494-3p/TGM2 Axis

Overview

Journal J Orthop Surg Res

Publisher Biomed Central

Specialty Orthopedics

Date 2021 Jan 13

PMID 33435987

Citations 18

Authors

Wei Wei

Liefeng Ji

Wanli Duan

Jiang Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Circular RNAs (circRNAs) have been shown to participate in the chemoresistance and tumorigenesis of multiple cancers. The purpose of this research was to investigate the function of circ_0081001 in methotrexate (MTX) resistance of osteosarcoma (OS) and its potential molecular mechanism.

Methods: The expression of circ_0081001, cytochrome P450 family 51 subfamily A member 1 (CYP51A1), and miR-494-3p was detected by qRT-PCR. Cell viability, apoptosis, migration, and invasion were evaluated by Cell Counting Kit-8 (CCK-8) assay, flow cytometry, and transwell assay, respectively. Western blot (WB) assay was used to measure the protein levels of cleaved-caspase3 (cleaved-casp3), E-cadherin, N-cadherin, and transglutaminase-2 (TGM2). The interaction between miR-494-3p and circ_0081001 or TGM2 was predicted by bioinformatics analysis and verified using the dual-luciferase reporter assay. The mice xenograft model was established to investigate the roles of circ_0081001 in MTX resistance of OS in vivo.

Results: Circ_0081001 and TGM2 were upregulated, and miR-494-3p was downregulated in MTX-resistant OS tissues and cells. Moreover, circ_0081001 interference enhanced cell sensitivity to MTX through promoting apoptosis and inhibiting cell viability and metastasis in vitro. Furthermore, circ_0081001 was identified as a molecular sponge of miR-494-3p to upregulate TGM2 level. In addition, circ_0081001 knockdown inhibited MTX resistance via upregulating miR-494-3p and downregulating TGM2. Besides, circ_0081001 downregulation improved MTX sensitivity of OS in vivo.

Conclusion: Knockdown of circ_0081001 enhanced MTX sensitivity of OS cells through downregulating TGM2 by sponging miR-494-3p, elucidating a novel regulatory mechanism for chemoresistance of OS and providing a potential circRNA-targeted therapy for OS.

Citing Articles

Research progress of circRNAs in bone-related diseases.

Hua X, Yu L, Zhu H, Zhu Y, Fan G, Zhou G Front Oncol. 2025; 15:1481322.

PMID: 39931083 PMC: 11807992. DOI: 10.3389/fonc.2025.1481322.

Hsa_circ_0078767 Enhances Osteosarcoma Chemoresistance to Doxorubicin Through the Regulation of the miR-188-3p/GPX4 Axis.

Tang Y, He Y, Wu L Pharmgenomics Pers Med. 2024; 17:511-520.

PMID: 39588535 PMC: 11586481. DOI: 10.2147/PGPM.S473702.

Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response.

Hashemi M, Khosroshahi E, Daneii P, Hassanpoor A, Eslami M, Koohpar Z Noncoding RNA Res. 2024; 10:98-115.

PMID: 39351450 PMC: 11440256. DOI: 10.1016/j.ncrna.2024.09.006.

Osteosarcoma in a ceRNET perspective.

Mosca N, Alessio N, Di Paola A, Marrapodi M, Galderisi U, Russo A J Biomed Sci. 2024; 31(1):59.

PMID: 38835012 PMC: 11151680. DOI: 10.1186/s12929-024-01049-y.

Role of microRNA-494 in tumor progression.

Maharati A, Akhlaghipour I, Taghehchian N, Yazdi Z, Moghbeli M Am J Transl Res. 2023; 15(11):6342-6361.

PMID: 38074823 PMC: 10703645.

References

Li X, Wang H, Wu Z, Yang T, Zhao Z, Chen G . miR-494-3p Regulates Cellular Proliferation, Invasion, Migration, and Apoptosis by PTEN/AKT Signaling in Human Glioblastoma Cells. Cell Mol Neurobiol. 2015; 35(5):679-87. PMC: 4477718. DOI: 10.1007/s10571-015-0163-0. View

Song L, Liu D, Wang B, He J, Zhang S, Dai Z . miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway. Oncol Rep. 2015; 34(1):525-31. DOI: 10.3892/or.2015.3965. View

Lin H, Huang Z, Liu J, Qiu Y, Tao Y, Wang M . MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN. Sci Rep. 2018; 8(1):10461. PMC: 6041272. DOI: 10.1038/s41598-018-28519-2. View

Huang L, Chen M, Pan J, Yu W . Circular RNA circNASP modulates the malignant behaviors in osteosarcoma via miR-1253/FOXF1 pathway. Biochem Biophys Res Commun. 2018; 500(2):511-517. DOI: 10.1016/j.bbrc.2018.04.131. View

Mirabello L, Troisi R, Savage S . Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115(7):1531-43. PMC: 2813207. DOI: 10.1002/cncr.24121. View

Fuja D, Rainusso N, Shuck R, Kurenbekova L, Donehower L, Yustein J . Transglutaminase-2 promotes metastatic and stem-like phenotypes in osteosarcoma. Am J Cancer Res. 2018; 8(9):1752-1763. PMC: 6176192. View

Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P . Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006; 106(5):1154-61. DOI: 10.1002/cncr.21724. View

Yuan W, Wang D, Liu Y, Tian D, Wang Y, Zhang R . miR‑494 inhibits cell proliferation and metastasis via targeting of CDK6 in osteosarcoma. Mol Med Rep. 2017; 16(6):8627-8634. PMC: 5779916. DOI: 10.3892/mmr.2017.7709. View

Kun-Peng Z, Xiao-Long M, Chun-Lin Z . Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. Int J Biol Sci. 2018; 14(3):321-330. PMC: 5859477. DOI: 10.7150/ijbs.24360. View

10.

Park M, Jo S, Lee H, Kang J, Kim Y, Kim H . Novel suppressive effects of cardamonin on the activity and expression of transglutaminase-2 lead to blocking the migration and invasion of cancer cells. Life Sci. 2012; 92(2):154-60. DOI: 10.1016/j.lfs.2012.11.009. View

11.

Li C, Gao Y, Li Y, Ding D . TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis. Biochem Biophys Res Commun. 2017; 491(2):552-557. DOI: 10.1016/j.bbrc.2017.03.042. View

12.

Zhang H, Yan J, Lang X, Zhuang Y . Expression of circ_001569 is upregulated in osteosarcoma and promotes cell proliferation and cisplatin resistance by activating the Wnt/β-catenin signaling pathway. Oncol Lett. 2018; 16(5):5856-5862. PMC: 6176349. DOI: 10.3892/ol.2018.9410. View

13.

Meyers P, Schwartz C, Krailo M, Healey J, Bernstein M, Betcher D . Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008; 26(4):633-8. DOI: 10.1200/JCO.2008.14.0095. View

14.

Chou A, Gorlick R . Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006; 6(7):1075-85. DOI: 10.1586/14737140.6.7.1075. View

15.

Chai J, Dong W, Xie C, Wang L, Han D, Wang S . MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. IUBMB Life. 2015; 67(3):191-201. DOI: 10.1002/iub.1361. View

16.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

17.

Chen L, Yang L . Regulation of circRNA biogenesis. RNA Biol. 2015; 12(4):381-8. PMC: 4615371. DOI: 10.1080/15476286.2015.1020271. View

18.

Zhou R, Wu Y, Wang W, Su W, Liu Y, Wang Y . Circular RNAs (circRNAs) in cancer. Cancer Lett. 2018; 425:134-142. DOI: 10.1016/j.canlet.2018.03.035. View

19.

Park K, Kim H, Lee J, Choi Y, Park S, Yang S . Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol. 2009; 136(4):493-502. DOI: 10.1007/s00432-009-0681-6. View

20.

Zheng T, Wang J, Chen X, Liu L . Role of microRNA in anticancer drug resistance. Int J Cancer. 2009; 126(1):2-10. DOI: 10.1002/ijc.24782. View